MedPath

Efficacy and safety of elobixibat in psychiatric disorders patients with chronic constipation -Retrospective observation research

Not Applicable
Conditions
Psychiatric disorders patients with chronic constipation
Registration Number
JPRN-UMIN000042139
Lead Sponsor
agisa clinic
Brief Summary

This study was a retrospective study on effectiveness and safety of elobixibat for chronic constipation in 28 psychiatric outpatients such as depression and schizophrenia. There was a significant increase in frequency of bowel movements per week, 4 and 52 weeks after treatment with elobixibat compared to that before the treatment. In addition, adverse events were observed in 3 patients, although those were not serious including mild diarrhea. (The Japanese Journal of Psychiatry. 2021; 26(6): 553-560)

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
28
Inclusion Criteria

Not provided

Exclusion Criteria

1. Patients with a history of hypersensitivity to elobixibat 2. Patients with confirmed or suspected bowel obstruction due to a tumor or hernia 3. Patients with suspected constipation due to organic disease 4. Patients diagnosed with dementia 5. Patients who have been determined by a physician to be inappropriate to administrate elobixibat

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath